Difluprednate

Difluprednate
Names
IUPAC name
  • [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
Clinical data
Drug classCorticosteroid[1]
Main usesPain and inflammation following eye surgery[1]
Side effectsInflammation of the eyelids, sensitivity to light, eye redness[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		Topical
External links
AHFS/Drugs.comMonograph
MedlinePlusa609025
Legal
License data
Legal status
Chemical and physical data
FormulaC27H34F2O7
Molar mass508.551 g·mol−1

Difluprednate (DFBA), sold under the brand name Durezol is a corticosteroid used to treat pain and inflammation following eye surgery.[1] It is used as an eye drop.[1] Those who use it should not wear contacts.[1]

Common side effects include inflammation of the eyelids, sensitivity to light, and eye redness.[1] Other side effects may include increased eye pressure, cataracts, slow healing, and infection.[2] Safety in pregnancy is unclear.[2]

Difluprednate was approved for medical use in the United States in 2008.[1] It is available as a generic medication.[3] In the United States 5 ml costs about 60 USD as of 2021.[3] It was originally made from prednisolone.[1]

Medical uses

Dosage

One drop is used 4 times per day.[1]

Chemistry

It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate.

History

On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[4] It is marketed by Alcon under the tradename Durezol.

Society and culture

Cost

The medication in the U.S. is $226 (USD) for 5 ml of ophthalmic emulsion 0.05% [5]

Research

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a }Phase 3 study evaluating difluprednate for the treatment of anterior uveitis[6][7]

References

  1. 1 2 3 4 5 6 7 8 9 10 "Difluprednate Monograph for Professionals". Drugs.com. Archived from the original on 29 September 2021. Retrieved 24 December 2021.
  2. 1 2 "DailyMed - DIFLUPREDNATE- difluprednate ophthalmic emulsion". dailymed.nlm.nih.gov. Archived from the original on 11 January 2022. Retrieved 26 December 2021.
  3. 1 2 "Difluprednate Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 19 May 2016. Retrieved 26 December 2021.
  4. ↑ "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Archived from the original on 2008-06-28. Retrieved 2008-06-30.
  5. ↑ "Durezol Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 August 2016. Retrieved 28 March 2021.
  6. ↑ Clinical trial number NCT00501579 for "Study of Difluprednate in the Treatment of Uveitis" at ClinicalTrials.gov
  7. ↑ Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS (May 2014). "Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study". Investigative Ophthalmology & Visual Science. 55 (5): 2993–3002. doi:10.1167/iovs.13-12660. PMC 4581692. PMID 24677110.
Identifiers:
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.